Hikma Pharmaceuticals, a leading multinational pharmaceutical group, will join the FTSE 100 Index, comprising the 100 most highly capitalised blue chip companies listed on the London Stock Exchange, as of March 24.

Mazen Darwazah, executive vice chairman, president and CEO of Mena and Emerging Markets at Hikma, said: “We are very pleased to be joining the FTSE 100 Index. Hikma has a long track record of growing by providing high quality, cost effective medicines to patients in the Mena region, the US and Europe.”

“Entry into the FTSE 100 Index marks the latest step in the Company’s journey. As a world class and leading speciality pharmaceutical company, Hikma will continue to grow and develop our business in a responsible manner,” he added.

Since it was founded in Amman, Jordan in 1978, Hikma has steadily grown into a leading speciality pharmaceutical group with a reputation for quality.

In the early 1990s, Hikma acquired a generic pharmaceuticals business in the United States and established an injectable pharmaceutical operation in Portugal, thereby expanding the company’s reach beyond the Mena region.

Hikma has since continued to expand significantly, through organic growth and acquisition, and now employs over 7,000 people around the world with 27 manufacturing plants and sales in over 50 countries. – TradeArabia News Service